HomeCIPLA • NSE
add
Cipla Ltd
Nakaraang pagsara
₹1,423.95
Sakop ng araw
₹1,426.00 - ₹1,469.80
Sakop ng taon
₹1,312.00 - ₹1,702.05
Market cap
1.18T INR
Average na Volume
1.46M
P/E ratio
23.64
Dividend yield
0.89%
Primary exchange
NSE
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (INR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 69.62B | 7.01% |
Gastos sa pagpapatakbo | 29.88B | 7.81% |
Net na kita | 15.71B | 48.74% |
Net profit margin | 22.56 | 39.00% |
Kita sa bawat share | 19.43 | 71.62% |
EBITDA | 19.19B | 10.19% |
Aktuwal na % ng binabayarang buwis | 17.43% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (INR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 87.08B | 78.06% |
Kabuuang asset | — | — |
Kabuuang sagutin | — | — |
Kabuuang equity | 284.56B | — |
Natitirang share | 807.46M | — |
Presyo para makapag-book | 4.05 | — |
Return on assets | — | — |
Return on capital | 14.78% | — |
Cash Flow
Net change in cash
| (INR) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 15.71B | 48.74% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
CEO
Itinatag
1935
Headquarters
Website
Mga Empleyado
27,764
